Bcal Diagnostics Limited · ASX:BDX
Bcal Diagnostics — Shareholder Meeting (November 2024)
21 slides from Bcal Diagnostics's shareholder meeting presentation, Nov 22, 2024
Slide 1: Annual General Meeting
BCAL DIAGNOSTICS LIMITED ASX: BDX Annual General Meeting DRIVING A NEW PARADIGM IN BREAST CANCER DIAGNOSTICS 22 November 2024 11.00 am (AEDT) CORPORATE PRESENTATION
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation (Presentation) has been prepared by BCAL Diagnostics The forward-looking statements are based on information available to BCAL Not An Offer Ltd ABN 51 142 051 223 (BCAL or the Company). as at the date of this Presentation. Circumstances may change an
Slide 3: Order of Proceedings
Item 1 Executive Chair’s Address Item 2 Financial Statement and Reports ORDER OF Item 3 Resolutions PROCEEDINGS Item 4 Chief Executive Officer’s Presentation Item 5 Other Business CORPORATE PRESENTATION 3
Slide 4: Board of Directors
BOARD OF DIRECTORS Jayne Hon Ron Mark Burrows Jonathan David John Hurrell Shaw Phillips AO AO Trollip Darling PhD Executive Chair Non-Executive Director Independent Independent Non-Executive Non-Executive Director and and Co-Founder and Co-Founder Non-Executive Director Non-Executive Director Direct
Slide 5: Company Metrics
COMPANY METRICS ASX Code BDX Share Price $0.11 18 November 2024 Shares on Issue 358.6M Unlisted Options 4.5M Cash 15 October 2024 $6.5M (+2.6M R&D rebate) Top 20 Shareholders 50% Management Shareholding 20% CORPORATE PRESENTATION 5
Slide 6: Chief Executive Officer's Presentation
Chief Executive Officer’s Presentation Shane Ryan CORPORATE PRESENTATION
Slide 7: Early Diagnosis Saves Lives and Costs to the Healthcare System
EARLY DIAGNOSIS SAVES LIVES AND COSTS TO THE HEALTHCARE SYSTEM } BREAST CANCER STAGES BCAL is focused on improving the outcomes for women with breast cancer STAGE 0 STAGE 1 STAGE 2 STAGE 3 STAGE 4 Modelling suggest more testing is needed… Annual 100% 98% 93% screening would reduce SURVIVAL SURVIVAL
Slide 8: Urgent Need to Get More Women Screened in Australia
THERE IS AN URGENT NEED TO GET MORE WOMEN SCREENED IN AUSTRALIA… BREASTEST® CAN HELP CLOSE THE SCREENING GAP Factors affecting screening participation 13% • Workforce challenges • Remoteness • Socioeconomic 52% / 1.9M • Currently, one size fits all model 56% / 4.7M 43% Australian women • Language(s)
Slide 9: Australian Commercial Launch on Track for Q1 CY2025
AUSTRALIAN COMMERCIAL LAUNCH ON TRACK FOR Q1 CY2025, AT THE SYDNEY BREAST CLINIC } Commercial strategy to advance relationships with existing partners to launch BREASTEST® in specialised clinics with first revenues expected to be delivered immediately following launch. Scheduled Imminent Has occurre
Slide 10: Corporate Highlights November 2024
CORPORATE HIGHLIGHTS NOVEMBER 2024 Product development NATA accreditation Sample collection Growing intellectual progress property Completed clinical study in collaboration NATA assessment of the North Ryde Over 5,000 samples from biopsy- A European patent was granted and with Precion Inc of North C
Slide 11: Corporate Highlights November 2024
CORPORATE HIGHLIGHTS NOVEMBER 2024 Clinical Advisory Board First peer-reviewed Capital raise First Commercial Partner - Australian breast publication cancer experts Established a Key Opinion Leader BCAL continued to enhance its scientific $10.5M capital raise Agreement in place with the Sydney Netwo
Slide 12: US Research and Product Development Commenced
US RESEARCH AND PRODUCT DEVELOPMENT COMMENCED Laboratory -Established BCAL US subsidiary, lease of US premises secured, and key laboratory equipment purchased -The US program offers BCAL an opportunity to accelerate and validate new products on US patient centric data and gain an in-county understan
Slide 13: Commercial Pathway
COMMERCIAL PATHWAY Australian Launch & US foundations Launch of BREASTEST® in Australia generating first revenues in Q1 CY 2025 01 Initial focus on NSW & VIC with existing strong clinical leadership and commercial partners BCAL roadmap to commercial launch underpinned by a reproducible Commerc
Slide 14: Australian Market Access Plan CY2025
AUSTRALIAN MARKET ACCESS PLAN CY2025 BREASTEST ® ADOPTION Existing +250 breast & Breast MDT Advocacy Groups champions across general surgeons Primary care / GPs (MO, BCN) NSW & VIC across Australia Breast specialist Broader healthcare teams system { Supported by Strategic Partnerships Rollout Q1: NS
Slide 15: Market Segmentation
MARKET SEGMENTATION } FOUR INITIAL KEY TARGET SEGMENTS Adjunct to current Dense breast tissue Those who are not screened Interval testing standard of care Phase 1 of launch; ~ 40% if women have dense or 1.5 million people who; 8/10,000 women will present with a extremely dense breast tissue; Sel
Slide 16: Clinic Advisory Board
CLINIC ADVISORY BOARD }Eminent and influential Breast Clinicians form a Breast Cancer Clinical Advisory Board to enhance trust, provide advice and inform the BCAL program Dr David Speakman Prof Bruce Mann Dr Corinne Ooi A/Prof. James French Prof. Elisabeth Elder Former Chief Medical Director of Brea
Slide 17: Highly Experienced Leadership Team
HIGHLY EXPERIENCED LEADERSHIP TEAM } With commercial expertise to drive BREASTEST® launch Shane Ryan MBA Dr David Speakman Kim Kirkham Dr Simon Preston PhD Dr Klaus-Peter Adam Chief Executive Officer Medical Laboratory Director & National Clinical Program Director Director Clinical Research Director
Slide 18: Pillars to Success in the Next 12 Months
PILLARS TO SUCCESS IN THE NEXT 12 MONTHS Market Access Strategy • Our main focus in the immediate future is delivering BREASTEST® to the Australian market. • Kim Kirkham, BCAL’s National Clinical Program Director, has developed a comprehensive market access plan. This will be rolled-out and leverage
Slide 19: Item 5 Other Business
ITEM 5 Other Business CORPORATE PRESENTATION 19
Slide 20: Questions
QUESTIONS CORPORATE PRESENTATION 20
Slide 21: Thank you
Thank you Jayne Shaw Shane Ryan Executive Chair Chief Executive Officer jshaw@bcaldiagnostics.com sryan@bcaldiagnostics.com DRIVING A NEW PARADIGM IN BREAST CANCER DIAGNOSTICS BCAL Diagnostics Limited ABN 51 142 051 223 Suite 506, Lvl 5, 50 Clarence Street Sydney NSW 2000 CORPORATE PRESENTATION 21 w
BCAL Diagnostics — Shareholder Meeting (November 2024) on 6ix